Register to receive a free U.S. Market for Wound and Tissue Management report synopsis and brochure
Tissue Regenix Wound Care Inc. announced that it has strengthened its position within the post-acute wound care market as they have received further approval for DermaPure® under Medicare administrator, First Coast Service Options Inc. whose jurisdiction includes Florida, Puerto Rico and the US Virgin Islands.
“Tissue Regenix continues to make significant progress in securing these critical approvals, not only allowing more patients to benefit from improved clinical outcomes, but demonstrating both the efficacy of the product and the strength of our hybrid commercialisation strategy,” said Chief Executive Officer Antony Odell in a statement.
With this approval, they have increased the number of Medicare beneficiaries to whom DermaPure® is available by 2.5 million. With prior approvals from Noridian Health Care Solutions, Palmetto GBA, Novitas Solutions and CGS Administrators within the first seven months of market availability, DermaPure® is now available across 31 States, the US Virgin Islands and Puerto Rico and is accessible to 37 million beneficiaries enrolled under the Medicare programme.
For Further Information
More on the wound closure market in the U.S. can be found in the report series published by iData entitled U.S. Market for Wound and Tissue Management. This report covers the U.S. markets for wound closure, static compression therapy, dynamic compression therapy, advanced dressing, moist dressing, antimicrobial dressing, interactive dressing, non-adherent contact layers, traditional wound dressing, hemostats, tissue sealants, anti-adhesions, and negative pressure wound therapy.
The iData series on the market for wound and tissue management devices covers the U.S., Brazil, China, India, Japan, South Korea, Australia, and 15 countries in Europe. Full reports also provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment.
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn-out body parts. The potential applications for this process are diverse and address many critical clinical needs such as treating vascular disease, heart valve replacement and knee repair.
About Reimbursement Tracker
iData Research’s Reimbursement Policy Tracker enables medical device, dental, pharmaceutical and healthcare professionals to receive real-time policy updates from hundreds of insurance companies and 60,000+ policies across all therapeutic areas in the United States.
About Procedure Tracker
Additional procedure number data is available from iData’s Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by country, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.
Explore our careers page for our current available job opportunities. This is your chance to join a fun and dynamic team in the medical market research industry. Send your resume to [email protected] with the job title in the subject line, and feel free to tell us a little about yourself. We look forward to hearing from you.